For years the answer to "is there a weight-loss pill that works like the shots" was no. That changed twice in four months. There are now two FDA-approved GLP-1 tablets for chronic weight management, and the coverage of both has been muddled enough that it is worth laying out plainly.
What is actually approved, and when
- ◆ Oral semaglutide, sold as Wegovy tablets at 25 mg once daily, was FDA-approved on December 22, 2025 for chronic weight management and to reduce the risk of major cardiovascular events in adults with overweight or obesity and established cardiovascular disease.
- ◆ Orforglipron, sold as Foundayo, was FDA-approved on April 1, 2026 for chronic weight management. It is not approved for type 2 diabetes.
You will see orforglipron described as the first oral GLP-1 approved for weight loss. It was not; oral semaglutide beat it by about three months. Lilly's own claim is narrower and accurate: Foundayo is the only weight-loss GLP-1 pill that can be taken at any time of day with no food or water restrictions. That turns out to be the difference that matters most in practice.
The dosing rule is the real decision point
Semaglutide is a peptide. Swallowed on its own it would be digested before it could be absorbed, so the tablet pairs it with an absorption enhancer, and even then only a small fraction of the dose gets through. That is why the oral version needs 25 mg daily to do what 2.4 mg weekly does by injection, and why the label is strict: empty stomach, no more than four ounces of plain water, then nothing to eat or drink and no other pills for at least 30 minutes.
Orforglipron is not a peptide. It is a conventional small molecule, so it behaves like an ordinary tablet: with or without food, any time of day, no waiting.
That distinction is not a footnote. If you take blood pressure medication at 7 a.m. with coffee, oral semaglutide asks you to rebuild your morning. Break the rule regularly and you are absorbing less drug than you think, which shows up later as a disappointing result rather than an obvious error.
About the 36 mg you keep reading about
The orforglipron trials used 6, 12 and 36 mg research doses, and the press still quotes them. The tablet you can actually be prescribed comes in 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg strengths. The maximum is 17.2 mg. Nobody is being prescribed 36 mg, and the FDA label reports the trial arms under their commercial equivalents.
You start at 0.8 mg and step up no faster than every 30 days. If you miss seven or more doses in a row, the label directs restarting the ramp at a lower dose rather than picking up where you left off.
How much weight, honestly
- ◆ Oral semaglutide 25 mg: about 13.6% average body-weight loss over 64 weeks counting everyone who started, and closer to 17% among those who stayed on treatment. Roughly three quarters lost at least 5%, and about one in three lost 20% or more.
- ◆ Orforglipron at the maximum dose: about 11.1% average over 72 weeks against 2.1% on placebo, or about 12.4% among those who stayed on treatment. About 36% lost 15% or more.
- ◆ For context, injectable semaglutide 2.4 mg averaged about 15% over 68 weeks, and tirzepatide averaged 16.0 to 22.5% over 72 weeks depending on dose.
Sources: Wharton S, Lingvay I, Bogdanski P, et al. N Engl J Med. 2025;393(11):1077-1087 (OASIS 4); Wharton S, Aronne LJ, Stefanski A, et al. N Engl J Med. 2025;393(18):1796-1806 (ATTAIN-1); Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002 (STEP 1); Jastreboff AM, et al. N Engl J Med. 2022 (SURMOUNT-1). These are separate trials in different populations, so cross-comparisons are indirect. Individual results vary.
Two cautions on that list. There is no head-to-head trial of either pill against injectable semaglutide or tirzepatide for weight loss, so any statement that a pill "matches the injections" is comparing across studies, not reporting a result. And the two pills have not been compared with each other for weight loss either. Treat the gaps between these numbers as suggestive, not decided.
Side effects are the same family, and dose-related
Both are GLP-1 receptor agonists, so the side-effect profile is the familiar one: nausea, diarrhea, vomiting, constipation, indigestion, mostly during dose escalation and mostly mild to moderate. On orforglipron's maximum dose the trial rates were nausea about 35%, diarrhea 25%, vomiting 24% and constipation 24%.
About 8% of orforglipron patients stopped because of side effects, against 3% on placebo, rising to roughly 10% at the top dose. Both drugs carry the class boxed warning about thyroid C-cell tumors seen in rodent studies, and both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. Neither should be combined with another GLP-1.
So who should actually take a pill?
Being needle-averse is a legitimate medical reason, not a weakness, and it is the clearest case for an oral option. A patient who will reliably take a tablet and would quietly abandon a weekly injection is better off on the pill, because a medication you actually take beats a more potent one you do not.
Beyond that, the split is practical. If your mornings are structured enough to protect a 30-minute window, oral semaglutide gives you more average weight loss and a cardiovascular indication. If they are not, orforglipron asks nothing of your schedule and costs you a few percentage points of expected result. And if needles genuinely do not bother you, the injectables still produce the largest average losses and have the longest track record, including four-year data. We will tell you that rather than steering you to whatever launched most recently.
The bottom line
Two real GLP-1 pills now exist, and neither is a compounded shortcut. Oral semaglutide wins on average result and carries a cardiovascular indication, but demands a disciplined empty-stomach routine. Orforglipron wins on convenience and asks for slightly lower expectations. Both sit below tirzepatide. Which one belongs in your plan depends on your goal, your tolerance, your coverage and your actual daily routine, which is a 20-minute conversation rather than a search result. Omnia Health prescribes branded, FDA-approved medications only, never compounded GLP-1s.
Keep reading
Medically reviewed by Dr. Roger Eduardo, MD, FASMBS, Board-Certified General Surgeon. This article is for general education and is not a substitute for personalized medical advice. Individual results vary. Omnia Health prescribes branded, FDA-approved medications only, never compounded.
